COMPETITIVITA' E DISPOSITIVI MEDICI: QUALE FUTURO?

La Nuova governance dei dispositivi Medici

Arezzo, 26/11/2024

agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI


HTA CG
MEMBER STATE COORDINATION GROUP
ON HEALTH TECHNOLOGY ASSESSMENT
Regulation on HTA: A new reality for Access to Innovation in Europe
Regulation (Eu) 2021/2282 on Health Technology Assessment (HTAR)
Marco Marchetti, MD
Director HTA Department, Agenzia Nazionale per i Servizi Sanitari Regionali (Agenas), Italy
Co-Chair, HTA Member State Coordination Group (HTACG), EU

The European Health Strategies



HTA CG

What is joint HTA at the EU level?



Nearly 600 people are working hard across all European HTA agencies to implement HTAR between HTACG and its subgroups

Article 7

Health technologies subject to joint clinical assessments

1. The following health technologies shall be subject to joint clinical assessments:

(a) medicinal products as referred to in Article 3(1) and Article 3(2), point (a), of Regulation (EC) No 726/2004, for which the application for a marketing authorisation is submitted in accordance with that Regulation after the relevant dates set out in paragraph 2 of this Article, and for which that application is in compliance with Article 8(3) of Directive 2001/83/EC;

(b) medicinal products authorised in the Union for which a joint clinical assessment report has been published, in cases where an authorisation is granted pursuant to the second subparagraph of Article 6(1) of Directive 2001/83/EC for a variation to an existing marketing authorisation which corresponds to a new therapeutic indication;

(c) **medical devices classified as class IIb or III pursuant to Article 51 of Regulation (EU) 2017/745 for which the relevant expert panels have provided a scientific opinion** in the framework of the clinical evaluation consultation procedure pursuant to Article 54 of that Regulation, and subject to selection pursuant to paragraph 4 of this Article;

(d) **in vitro diagnostic medical devices classified as class D pursuant to Article 47 of Regulation (EU) 2017/746 for which the relevant expert panels have provided their views** in the framework of the procedure pursuant to Article 48(6) of that Regulation, and subject to selection pursuant to paragraph 4 of this Article

EU HTAR governance structure



HTA Stakeholder Network

Include patients associations, non governmental organization in the filed of health, health technology developers and health professional.

Facilities dialogues between stakeholder oerganizations and the HTA Coordination Group

Members are umbrela organizations with geoghrapical coverage of several EU/EEA Member States

HTAR is the first example of co-legislation
Member States are driving the implementation of the regulation

What are key activities for whom?

EMA	EU HTA Regulation	NATIONAL
• Single licensing system • EU legislation • Well-defined and agreed assessment criteria	• Joint framework for clinical assessment • Common methodology and approach for clinical assessments and scientific consultations	• Use of joint clinical assessment in national decision-making • Non-clinical assessments • Decision making on pricing and reimbursements

EU HTAR entered into force in 2022, building on a decade cross-borde HTA experience in the EU

IMPLEMENTATION TIMELINES AND SCOPE



SUPPORTED BY EU AND NATIONAL HTAR READINESS PROGRAMS

EU HTAR Implementing Acts

Procedural rules for JCA of medicinal products	ADOPTED
Procedural rules for the management of conflict of interest	ADOPTED
Rules on cooperation by exchange of information with the EMA	ADOPTED
Procedural rules for JSC of medicinal products	**Q4 2024 –Public consultation will close on October 2024**
Procedural rules for JSC of medical devices and IVD medical devices	**Q4 2024**
Procedural rules for JCA of medical devices and IVD medical devices	**Q4 2024**

Guidance Documents

Methodological Guidance	Adoption by CG
Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons	8 March 2024
Practical Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons	8 March 2024
Guidance on outcomes for joint clinical assessments	13 June 2024
Guidance on reporting requirements for multiplicity issues and subgroup, sensitivity and post hoc analyses in joint clinical assessments	13 June 2024
Scientific specifications of medicinal products subject to joint clinical assessments	13 June 2024
Guidance on the validity of clinical studies for joint clinical assessments	19 September 2024
Guidance on Scoping Process	28 November 2024
Guidance on procedural steps and timeframe for joint clinical assessments	28 November 2024
Guidance on filling in the joint clinical assessment (JCA) dossier template – Medicinal products and Table template collection for guidance on filling in the joint clinical assessment (JCA) dossier template – Medicinal Products	28 November 2024
Guidance for the appointment of assessors and co-assessors for joint clinical assessments and joint scientific consultations	28 November 2024
Procedural guidance for joint scientific consultation on medicinal products	28 November 2024
Guidance for the selection of joint scientific consultations for medicinal products	28 November 2024
Format and template (Medicinal Products) of requests from health technology developers for joint scientific consultation, the dossier submitted by the health technology developer and the outcome document for JSC.	28 November 2024

EU4Health | To build a long-term capacity and knowledge for the HTAR implementation

NEED ASSESSMENT SURVEY COMPLETED

~500 people to receive trainings



Procedural and methods are key need areas



TRAINING PROGRAM FOR A LONG-TERM HTAR CAPACITY

HAG- INSIGHT
Head of Agencies Group
Initiative for Knowledge and Skill Enhancement in Health Technology Assessment Regulation

HTAR Implementation national readiness programs

HTAR implementation: Preparations advancing towards covering 40% of EU citizens

Technical Support Instrument (TSI)



**Country sizes are readjusted for visibility, may not represent actual relative sizes (e.g. Malta), Some country distant islands may not be visible due to sizing adjustments.*

Supporting the successful implementation of the Regulation UE 2021/2282 on health technology assessment by HAS

Reorganization of Italian national governance

Strengthening the national framework for the implementation of the EU HTA Regulation 2021/2282: capacity building and harmonization

Supporting the successful implementation of the EU Health Technology Assessment Regulation by AEMP

Support for the implementation of the EU Health Technology Assessment Regulation
Implementation of the HTA Legislation in Malta
Supporting the establishment of HTA procedures to ensure a successful implementation of the Regulation UE 2021/2282 on health technology assessment

The MDs processes under the MDR, IVDR and HTAR



HTAR Readiness Italy – Medical Devices

agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

Landing HTA Regulation:– Case of Italy Medical Devices

NATIONAL PROGRAM FOR HEALTH TECHNOLOGY ASSESSMENT FOR MEDICAL DEVICES

PNHTA 2023-2025

What's the PNHTA 2023-2025?

The National Health Technology Assessment Program for medical devices is a national initiative spanning three years, with the primary objective of critically assessing and integrating health technologies into the framework of the National Health Service (SSN).

**Legislative decrees n.137 and n. 138 August 5 2022*
Ministry of Health decree 9 June 2023 "Adozione del Programma Nazionale HTA"

agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

NATIONAL PROGRAM FOR HEALTH TECHNOLOGY ASSESSMENT FOR MEDICAL DEVICES PNHTA 2023-2025

Main Objectives

Production of HTA report.

Transfer and implementation of the HTA results within the National Health Service.

Scope

Ensuring the efficiently allocation of healthcare resources, promoting equitable access to health technologies, and enhancing the quality of care.

agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

PNHTA - Process steps

Process steps



agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

Governance Structure of the PNHTA 2023-2025



agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

Integration area with the PNHTA 2023-2025



agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI



A potential benchmark for the Governance System for Medical Devicesi nItaly

https://www.agenas.gov.it/i-quaderni-di-monitor-%E2%80%93-supplementi-alla-rivista/2544-la-governance-dei-dispositivi-medici-in-francia-dalle-valutazioni-hta-alla-rimborsabilit%C3%A0-e-al-prezzo-dei-dispositivi-medici

agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

AGENAS

AGENAS AREE TEMATICHE PROGETTI DI RICERCA COMUNICAZIONE PNRR PORT

La governance dei dispositivi medici in Francia: dalle valutazioni HTA alla rimborsabilità e al prezzo dei dispositivi medici

La governance dei dispositivi medici in Francia:
dalle valutazioni HTA alla rimborsabilità e al prezzo dei dispositivi medici

Anno 2024

Scarica il Supplemento - Lettura digitale
Scarica il Supplemento - Per stampa

Ultima modifica: 22 Novembre 2024

Visite: 100

Accesso al percorso di rimborsabilità



Intercommissioni: CNEDiMTS (Commissione valutazione DM) + CEESP
(Commissione valutazione economica e della salute pubblica)



agenas AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

Thank you
marchetti@agenas.it